Merck (MRK.US) expects revenue of $56.1 billion to $57.6 billion this year

2022-05-11 0 By

Merck has delivered 1.4 million doses of Molnupiravir worth $952 million to the United States, the United Kingdom and Japan after the US Food and Drug Administration (FDA) approved the drug in December last year, according to the company’s financial report.The company will deliver an additional 3.1 million doses to customers worldwide in the coming days, with another 4 million doses soon to be distributed.Merck and Ridgeback will split the proceeds from the sale of Molnupiravir equally.Merck chief Executive Rob Davis said Davis was pleased with the start of sales of Molnupiravir and was confident it would meet its sales targets for the year.Merck expects revenue of $56.1 billion to $57.6 billion this year, up as much as 18 percent from last year’s $48.7 billion.Group finance director Caroline Litchfield said Molnupiravir was the main driver of revenue growth.